Drug intelligence / Profile preview

TSRF 786C

Development stage: Preclinical
Lead developer: Tasrif Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

TSRF 786C is a fully humanized IgG4 S241P monoclonal antibody being developed by Tasrif Pharmaceutical as an anticancer immunotherapy for brain and systemic malignancies that express the poliovirus receptor CD155, also known as PVR. The antibody is designed to bind PVR and block the PVR TIGIT immune checkpoint axis, a pathway implicated in tumor immune evasion. Available information describes TSRF 786C as a potential best in class anti PVR antibody with high affinity and specificity in preclinical studies, along with low predicted immunogenicity and a low risk of infusion reaction; as of the available source context, it was in preclinical development.

Other names: hinge stabilized IgG4 fully humanized monoclonal antibody against PVR (CD155)

Targets

PVR

Beyond the preview

Go deeper on TSRF 786C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TSRF 786C.

Explore the full profile